Highest-materiality recent filing
Envista CAO Faez Kaabi to retire Aug 6, 2026; Coree Thomas appointed successor
Faez Kaabi notified resignation as CAO and principal accounting officer effective Aug 6, 2026, due to retirement.
Stockholders elected all eight director nominees: votes for ranged from 145,760,570 to 149,459,395.
Envista Q1 2026: core sales +9.5%, adjusted EPS $0.36 (+50% YoY), new $300M buyback
Revenue $706M, core sales growth 9.5% YoY; Specialty Products +8.4%, Equipment & Consumables +11.5%.
Envista Q4 2025: core revenue +10.8%, adj. EPS $0.38 (+58% YoY); FY 2026 guidance issued
Q4 2025 revenue $751M; core sales +10.8% YoY; GAAP EPS $0.20; adjusted EPS $0.38 (+58%).
Envista releases 2024 Sustainability Report; $1.9M donated, safety incident rate down 13%
Donated $1.9M in goods/services via Envista Smile Project to expand oral care access for underserved communities.
Q3 sales $670M, core sales growth 9.4% YoY; all major businesses positive growth.
Director Barbara B. Hulit resigns from Envista board effective Sept 26, 2025
Barbara B. Hulit submitted her resignation from the Board on September 15, 2025.
Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15
Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).
Envista appoints Stryker executive J. Andrew Pierce to Board, adds Audit Committee role
J. Andrew Pierce elected to Board effective July 14, 2025, expanding Board from 8 to 9 members.
Envist stockholders approve all four proposals at 2025 annual meeting
All eight director nominees elected with >99% support for most.
Envista Q1 sales $617M, adj. EPS $0.24, maintains 2025 guidance
Sales $617M, core sales +0.2% YoY; net income $18M, adjusted net income $42M.
Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05
Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.
Envista authorizes $250M share repurchase program through Dec 31, 2026
Board authorized repurchase of up to $250 million in common stock.
Envista releases 2023 Sustainability Report with 26% reduction in Scope 1 GHG emissions
Absolute Scope 1 GHG emissions decreased 26% year-over-year; total (Scope 1+2) intensity down 3.5%.
Envista Q3: net income $8.2M ($0.05 EPS), core sales down 5.3%, adj EBITDA $54.9M
GAAP net income $8.2M ($0.05 diluted EPS) vs $21.5M ($0.12) in Q3 2023.
Envista Q2 net loss $1.15B on $1.15B goodwill impairment; guides FY core sales down 1-4%
Net loss $1,151.6M ($6.69 per share) includes $1,153.8M non-cash goodwill and intangible impairment.
Eric Hammes appointed CFO effective August 8, 2024; interim CFO Stephen Keller returns to lead investor relations.
Envista's SVP & President of Orthodontics Eric Conley steps down effective June 3
Eric Conley notified Envista on May 27, 2024, that he will step down as SVP and President, Orthodontics.
Envista annual meeting results: officer exculpation approved, Paul Keel elected director
Charter amendment to exculpate officers approved: 130.7M for, 27.6M against, effective May 21, 2024.
Envista Q1 net income $23.6M, adjusted EPS $0.26 (down 32% YoY); Paul Keel appointed CEO
Reported sales $623.6M, core sales up 0.4% YoY.
Envista appoints Paul Keel as CEO effective May 1, 2024; succeeds Amir Aghdaei
Paul Keel, former CEO of Smiths Group plc, named President & CEO and board member effective May 1, 2024.
Envista director Barbara Hulit terminates consulting agreement, effective Apr 30, 2024
Consulting agreement with director Barbara Hulit signed Jan 2, 2024, for 180-day term.
Envista announces planned CEO succession; Aghdaei to step down once successor appointed
CEO Amir Aghdaei to step down upon appointment of successor; board formed search committee for external candidates.
Envista Q4 net loss $217.4M on $258.3M impairment; adjusted EPS $0.29; guides FY2024 margin 16-17%
Q4 reported sales $645.6M, core sales down 2.0% YoY; net loss of $1.27 diluted EPS includes $258.3M goodwill/intangibles impairment.
Envista names three new executives; Nobel Biocare president exits Dec 31
Patrik Eriksson, SVP and President of Nobel Biocare, departs effective Dec 31, 2023.
Faez Kaabi notified Envista Holdings Corporation (the “Company”) of his intention to resign as Chief Accounting Officer and principal accounting officer of the Company effective as of August 6, 2026.
On June 2, 2026, the Company appointed Coree Thomas, the Company’s Vice President, Global Controller, as the Company’s Vice President and Chief Accounting Officer.
On July 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Eric Hammes as the Senior Vice President and Chief Financial Officer of the Company, with such appointment to be effective as of August 8, 2024.
On April 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Paul Keel as the President and Chief Executive Officer of the Company, with such appointment to be effective as of May 1, 2024
On February 22, 2024, Envista Holdings Corporation (the “Company”) and Amir Aghdaei, the President and Chief Executive Officer of the Company, entered into a transition letter agreement (the “Transition Agreement”), setting forth the terms of Mr. Aghdaei’s anticipated transition from his position as the Company’s President and Chief Executive Officer.
On December 11, 2023, Envista Holdings Corporation (the “Company”) and Patrik Eriksson, the Company’s SVP and President, Nobel Biocare, mutually agreed that Mr. Eriksson’s employment will terminate effective December 31, 2023.
Max materiality 0.85 · Median 0.65 · Most common event earnings